Advanced ovarian cancer in the elderly: Results of consecutive trials with cisplatin-based chemotherapy

Critical Reviews in Oncology/Hematology

Volumn 37, Issue 1, 2001, Pages 27-34

  Chiara, Silvana ^a   Lionetto, Rita ^a   Vincenti, Maura ^a   Bruzzone, Milena ^a   Nobile, Maria Teresa ^a   Gadducci, Angiolo ^b   Carnino, Flavio ^c   Rosso, Riccardo ^a   Conte, PierFranco ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c S ANNA HOSPITAL   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Chemotherapy; Cisplatin; Elderly; Ovarian cancer

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHYLPREDNISOLONE; METOCLOPRAMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MULTIPLE REGRESSION; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; SIDE EFFECT; STOMATITIS; VOMITING;

EID: 0035148184     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00088-3     Document Type: Review

References (24)

1. Ovarian cancer. Survival and treatment by age
2. A randomized trial comparing platinum plus cyclophosphamide versus platinum, doxorubicin and cyclophosphamide in advanced ovarian cancer
3. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: a randomized trial in stage III-IV ovarian carcinoma
4. High versus low dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer. A randomized study of the Gruppo Oncologico Nord-Ovest
5. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the GONO
6. Non-parametric estimation from incomplete observations
7. Regression model and life tables
8. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia
9. The prognosis of Hodgkin's disease in older adults
10. A predictive model for aggressive non-Hodgkin's lymphoma
11. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group
12. Prognostic factors for survival in advanced non-small cell lung cancer. Univariate and multivariate analyses including recursive partitioning amalgamation algorithms in 1052 patients
13. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy
14. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stage III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group Study
15. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group Experience
16. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group Studies
17. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary
18. Long-term prognosis following macroscopic complete response at second look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy
19. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
20. Paclitaxel (175 mg/mq over 3 h) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis
21. No increased risk of taxol toxicity in older patients
22. Phase 1 and pharmacologic study of paclitaxel administered weekly in patents with relapsed ovarian cancer
23. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion
24. Gastrointestinal cancer in the elderly